Bristol-Myers Squibb (Diabetes Business) is Drug Discovery in United States that focus on pramlintide acetate business. They cover business area such as developer, supplier, diabetes product, diabetes medication, Onglyza, (saxagliptin, Kombiglyze XR, saxagliptin and metformin HCl, release, Forxiga, Farxiga, Xigduo, Byetta, injectable suspension, metreleptin, Symlin, pramlintide acetate.
-
Pramlintide Acetate
-
345 Park Avenue
New York, NY 10154
United States
Private
developersupplierdiabetes productdiabetes medicationOnglyza(saxagliptinKombiglyze XRsaxagliptin and metformin HClreleaseForxigaFarxigaXigduoByettainjectable suspensionmetreleptinSymlinpramlintide acetate
* We use standard office opening hours in near Bristol-Myers Squibb (Diabetes Business)'s location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Bristol-Myers Squibb (Diabetes Business) is Drug Discovery business from United States that founded in - ( years old in ), Bristol-Myers Squibb (Diabetes Business) business is focusing on Pramlintide Acetate.
Bristol-Myers Squibb (Diabetes Business) headquarter office and corporate office address is located in 345 Park Avenue New York, NY 10154 United States.
Bristol-Myers Squibb (Diabetes Business) was founded in United States.
In , Bristol-Myers Squibb (Diabetes Business) is currently focus on pramlintide acetate sector.
Above is snippet of Google Trends for "pramlintide acetate" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Bristol-Myers Squibb (Diabetes Business), any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
